Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel Free NRSNW Stock Alerts

NeuroSense Therapeutics (NRSNW) Competitors

$0.10 -0.02 (-15.75%)
As of 10:18 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

NRSNW vs. ALVOW, APLMW, ARAV, BIAFW, and BIVIW

Should you buy NeuroSense Therapeutics stock or one of its competitors? NeuroSense Therapeutics's main competitors and comparable companies include Alvotech (ALVOW), Apollomics (APLMW), Aravive (ARAV), bioAffinity Technologies (BIAFW), and BioVie (BIVIW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does NeuroSense Therapeutics compare to Alvotech?

Alvotech (NASDAQ:ALVOW) and NeuroSense Therapeutics (NASDAQ:NRSNW) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

Company Net Margins Return on Equity Return on Assets
AlvotechN/A N/A N/A
NeuroSense Therapeutics N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alvotech$559.42MN/AN/AN/AN/A
NeuroSense TherapeuticsN/AN/AN/AN/AN/A

In the previous week, Alvotech had 1 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 2 mentions for Alvotech and 1 mentions for NeuroSense Therapeutics. NeuroSense Therapeutics' average media sentiment score of 1.89 beat Alvotech's score of 0.93 indicating that NeuroSense Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Alvotech Positive
NeuroSense Therapeutics Very Positive

Summary

Alvotech beats NeuroSense Therapeutics on 2 of the 3 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to Apollomics?

NeuroSense Therapeutics (NASDAQ:NRSNW) and Apollomics (NASDAQ:APLMW) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

Company Net Margins Return on Equity Return on Assets
NeuroSense TherapeuticsN/A N/A N/A
Apollomics N/A N/A N/A

In the previous week, Apollomics had 2 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 3 mentions for Apollomics and 1 mentions for NeuroSense Therapeutics. NeuroSense Therapeutics' average media sentiment score of 1.89 beat Apollomics' score of 0.29 indicating that NeuroSense Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
NeuroSense Therapeutics Very Positive
Apollomics Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NeuroSense TherapeuticsN/AN/AN/AN/AN/A
Apollomics$8.50MN/AN/AN/AN/A

Summary

Apollomics beats NeuroSense Therapeutics on 2 of the 3 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to Aravive?

Aravive (NASDAQ:ARAV) and NeuroSense Therapeutics (NASDAQ:NRSNW) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Company Net Margins Return on Equity Return on Assets
AraviveN/A N/A N/A
NeuroSense Therapeutics N/A N/A N/A

35.8% of Aravive shares are owned by institutional investors. 60.4% of Aravive shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AraviveN/AN/AN/A-$0.90N/A
NeuroSense TherapeuticsN/AN/AN/AN/AN/A

In the previous week, NeuroSense Therapeutics had 1 more articles in the media than Aravive. MarketBeat recorded 1 mentions for NeuroSense Therapeutics and 0 mentions for Aravive. NeuroSense Therapeutics' average media sentiment score of 1.89 beat Aravive's score of 0.00 indicating that NeuroSense Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Aravive Neutral
NeuroSense Therapeutics Very Positive

Summary

Aravive and NeuroSense Therapeutics tied by winning 2 of the 4 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to bioAffinity Technologies?

NeuroSense Therapeutics (NASDAQ:NRSNW) and bioAffinity Technologies (NASDAQ:BIAFW) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

In the previous week, bioAffinity Technologies had 1 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 2 mentions for bioAffinity Technologies and 1 mentions for NeuroSense Therapeutics. NeuroSense Therapeutics' average media sentiment score of 1.89 beat bioAffinity Technologies' score of 0.97 indicating that NeuroSense Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
NeuroSense Therapeutics Very Positive
bioAffinity Technologies Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NeuroSense TherapeuticsN/AN/AN/AN/AN/A
bioAffinity Technologies$5.61MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
NeuroSense TherapeuticsN/A N/A N/A
bioAffinity Technologies N/A N/A N/A

Summary

bioAffinity Technologies beats NeuroSense Therapeutics on 2 of the 3 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to BioVie?

BioVie (NASDAQ:BIVIW) and NeuroSense Therapeutics (NASDAQ:NRSNW) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

In the previous week, BioVie had 1 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 2 mentions for BioVie and 1 mentions for NeuroSense Therapeutics. NeuroSense Therapeutics' average media sentiment score of 1.89 beat BioVie's score of 1.87 indicating that NeuroSense Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
BioVie Very Positive
NeuroSense Therapeutics Very Positive

Company Net Margins Return on Equity Return on Assets
BioVieN/A N/A N/A
NeuroSense Therapeutics N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioVieN/AN/AN/AN/AN/A
NeuroSense TherapeuticsN/AN/AN/AN/AN/A

Summary

BioVie and NeuroSense Therapeutics tied by winning 1 of the 2 factors compared between the two stocks.

Get NeuroSense Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NRSNW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRSNW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NRSNW vs. The Competition

Export
MetricNeuroSense TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$3.75B$7.05B$13.07B
Dividend YieldN/A3.76%2.58%10.74%
P/E RatioN/A10.42268.9125.20
Price / SalesN/A1,273.52644.96105.94
Price / CashN/A102.9470.5950.58
Price / BookN/A17.7513.146.27
Net IncomeN/A-$13.23M$3.45B$347.55M
7 Day PerformanceN/A3.11%2.27%1.95%
1 Month PerformanceN/A1.58%1.38%1.10%
1 Year PerformanceN/A55.44%68.12%19.62%

NeuroSense Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NRSNW
NeuroSense Therapeutics
N/A$0.10
-15.8%		N/A-85.5%$0.00N/AN/A10
ALVOW
Alvotech
N/A$0.15
flat		N/AN/A$0.00$559.42MN/A4
APLMW
Apollomics
N/A$0.02
+16.4%		N/A-29.3%$0.00$8.50MN/A59
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
BIAFW
bioAffinity Technologies
N/A$0.07
+0.9%		N/A-30.7%$0.00$5.61MN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NRSNW) was last updated on 8/13/2026 by MarketBeat.com Staff.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
What's the Best Way to Lower RMD Taxes?
Once you turn 73, the IRS requires you to take distributions from your IRA, 401(k), and other retirement accou...
SmartAsset | Sponsoredtc pixel
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel